Cutaneous Adverse Reactions Associated with Monoclonal Antibodies Treatment in Multiple Sclerosis: Case Reports and Short Literature Review
Background and aims. Multiple sclerosis is a disease of the central nervous system, whose treatment often involves the use of monoclonal antibodies. This can lead to a series of complications that the clinician should pay attention to and accordingly adjust the therapy. We aim to emphasize real-life...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/13/3702 |
| _version_ | 1797408881760010240 |
|---|---|
| author | Carmen Adella Sirbu Raluca Ivan Titus Mihai Vasile Lucian George Eftimie Daniel Octavian Costache |
| author_facet | Carmen Adella Sirbu Raluca Ivan Titus Mihai Vasile Lucian George Eftimie Daniel Octavian Costache |
| author_sort | Carmen Adella Sirbu |
| collection | DOAJ |
| description | Background and aims. Multiple sclerosis is a disease of the central nervous system, whose treatment often involves the use of monoclonal antibodies. This can lead to a series of complications that the clinician should pay attention to and accordingly adjust the therapy. We aim to emphasize real-life experiences with adverse cutaneous reactions to monoclonal antibodies by presenting a series of two cases from our clinic. Methods. In the first case, a female patient was treated with natalizumab for eight years and developed relapsing-remitting cutaneous lesions following the monthly administration of the treatment. The second case is of a male patient treated with ocrelizumab, who developed plaque-like lesions following the fifth administration. We analyzed the biological parameters and performed investigations, dermatological evaluation and skin biopsies. Results. The result of the skin biopsy for the natalizumab patient showed a chronic spongiotic dermatitis, with the anti-natalizumab antibodies being negative. The patient who received ocrelizumab developed nummular eczema, disseminated on his trunk and limbs. Conclusions. Given the fact that these therapies are frequently used in multiple sclerosis patients, and their skin adverse reactions are known, we described some particularities and a brief review of the literature with practical implications. Further studies need to be conducted to establish a firm association between monoclonal antibodies therapy and adverse cutaneous reactions, but the clinician should be aware of their existence. |
| first_indexed | 2024-03-09T04:06:03Z |
| format | Article |
| id | doaj.art-de7da9b0bd9e4eadabafbce36b33b103 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T04:06:03Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-de7da9b0bd9e4eadabafbce36b33b1032023-12-03T14:07:46ZengMDPI AGJournal of Clinical Medicine2077-03832022-06-011113370210.3390/jcm11133702Cutaneous Adverse Reactions Associated with Monoclonal Antibodies Treatment in Multiple Sclerosis: Case Reports and Short Literature ReviewCarmen Adella Sirbu0Raluca Ivan1Titus Mihai Vasile2Lucian George Eftimie3Daniel Octavian Costache4Department of Neurology, ‘Dr. Carol Davila’ Central Military Emergency University Hospital, 010242 Bucharest, RomaniaDepartment of Neurology, ‘Dr. Carol Davila’ Central Military Emergency University Hospital, 010242 Bucharest, RomaniaClinical Neurosciences Department, University of Medicine and Pharmacy “Carol Davila” Bucharest, 050474 Bucharest, RomaniaDepartment of Pathology, ‘Dr. Carol Davila’ Central Military Emergency University Hospital, 010242 Bucharest, RomaniaDepartment of Dermatology, ‘Dr. Carol Davila’ Central Military Emergency University Hospital, 010242 Bucharest, RomaniaBackground and aims. Multiple sclerosis is a disease of the central nervous system, whose treatment often involves the use of monoclonal antibodies. This can lead to a series of complications that the clinician should pay attention to and accordingly adjust the therapy. We aim to emphasize real-life experiences with adverse cutaneous reactions to monoclonal antibodies by presenting a series of two cases from our clinic. Methods. In the first case, a female patient was treated with natalizumab for eight years and developed relapsing-remitting cutaneous lesions following the monthly administration of the treatment. The second case is of a male patient treated with ocrelizumab, who developed plaque-like lesions following the fifth administration. We analyzed the biological parameters and performed investigations, dermatological evaluation and skin biopsies. Results. The result of the skin biopsy for the natalizumab patient showed a chronic spongiotic dermatitis, with the anti-natalizumab antibodies being negative. The patient who received ocrelizumab developed nummular eczema, disseminated on his trunk and limbs. Conclusions. Given the fact that these therapies are frequently used in multiple sclerosis patients, and their skin adverse reactions are known, we described some particularities and a brief review of the literature with practical implications. Further studies need to be conducted to establish a firm association between monoclonal antibodies therapy and adverse cutaneous reactions, but the clinician should be aware of their existence.https://www.mdpi.com/2077-0383/11/13/3702multiple sclerosismonoclonal antibodiesnatalizumabocrelizumabadverse skin reactions |
| spellingShingle | Carmen Adella Sirbu Raluca Ivan Titus Mihai Vasile Lucian George Eftimie Daniel Octavian Costache Cutaneous Adverse Reactions Associated with Monoclonal Antibodies Treatment in Multiple Sclerosis: Case Reports and Short Literature Review Journal of Clinical Medicine multiple sclerosis monoclonal antibodies natalizumab ocrelizumab adverse skin reactions |
| title | Cutaneous Adverse Reactions Associated with Monoclonal Antibodies Treatment in Multiple Sclerosis: Case Reports and Short Literature Review |
| title_full | Cutaneous Adverse Reactions Associated with Monoclonal Antibodies Treatment in Multiple Sclerosis: Case Reports and Short Literature Review |
| title_fullStr | Cutaneous Adverse Reactions Associated with Monoclonal Antibodies Treatment in Multiple Sclerosis: Case Reports and Short Literature Review |
| title_full_unstemmed | Cutaneous Adverse Reactions Associated with Monoclonal Antibodies Treatment in Multiple Sclerosis: Case Reports and Short Literature Review |
| title_short | Cutaneous Adverse Reactions Associated with Monoclonal Antibodies Treatment in Multiple Sclerosis: Case Reports and Short Literature Review |
| title_sort | cutaneous adverse reactions associated with monoclonal antibodies treatment in multiple sclerosis case reports and short literature review |
| topic | multiple sclerosis monoclonal antibodies natalizumab ocrelizumab adverse skin reactions |
| url | https://www.mdpi.com/2077-0383/11/13/3702 |
| work_keys_str_mv | AT carmenadellasirbu cutaneousadversereactionsassociatedwithmonoclonalantibodiestreatmentinmultiplesclerosiscasereportsandshortliteraturereview AT ralucaivan cutaneousadversereactionsassociatedwithmonoclonalantibodiestreatmentinmultiplesclerosiscasereportsandshortliteraturereview AT titusmihaivasile cutaneousadversereactionsassociatedwithmonoclonalantibodiestreatmentinmultiplesclerosiscasereportsandshortliteraturereview AT luciangeorgeeftimie cutaneousadversereactionsassociatedwithmonoclonalantibodiestreatmentinmultiplesclerosiscasereportsandshortliteraturereview AT danieloctaviancostache cutaneousadversereactionsassociatedwithmonoclonalantibodiestreatmentinmultiplesclerosiscasereportsandshortliteraturereview |